Skip to main content

Table 2 Transcripts identified as over-expressed in ERα (+) breast cancers commonly detected by cross-platforms comparison (SAGE and oligonucleotide microarrays).

From: Gene expression signature of estrogen receptor α status in breast cancer

Gene name Locus Link ID Fold change Frequency Gene name Locus Link Fold change Frequency#
TFF1* 7031 51.4 15/18 (83%) SULF2 55959 2.9 11/18 (61%)
SYTL4* 94121 28.0 15/18 (83%) THBS4 7060 2.9 8/18 (44%)
DUSP4 1846 14.7 14/18 (78%) AZGP1 563 2.8 9/18 (50%)
NAT1 9 11.7 15/18 (83%) BBC3* 27113 2.8 12/18 (67%)
ECM1* 1893 10.1 13/18 (72%) NET7* 23555 2.8 10/18 (55%)
KIAA0882 23158 10.1 18/18 (100%) NET6 27075 2.8 12/18 (67%)
JDP1 56521 10.0 12/18 (67%) TRAF5 7188 2.8 9/18 (50%)
ESR1 2099 9.8 18/18 (100%) BTG2 7832 2.7 9/18 (50%)
HDGFRP3 50810 9.8 12/18 (67%) RNF123* 63891 2.7 11/18 (61%)
TCEAL1 9338 9.8 13/18 (72%) CHAD* 1101 2.6 12/18 (67%)
TSPAN1* 10103 9.5 15/18 (83%) CSNK1A1 1452 2.6 14/18 (78%)
C20orf103* 24141 9.3 10/18 (55%) EVL 51466 2.6 12/18 (67%)
MYLIP 29116 9.3 11/18 (61%) HIST1H2BD 3017 2.6 10/18 (55%)
ABCA3 21 8.9 10/18 (55%) SUSD3 203328 2.6 9/18 (50%)
SEC14L2 23541 8.7 9/18 (50%) PLAT* 5327 2.6 8/18 (44%)
ANXA9* 8416 8.4 10/18 (55%) RARRES3* 5920 2.6 11/18 (61%)
KCTD3 51133 8.4 17/18 (94%) SH3BGRL* 6451 2.6 8/18 (44%)
SCUBE2 57758 7.5 14/18 (78%) TPBG* 7162 2.6 9/18 (50%)
ITGBL1 9358 7.1 8/18 (44%) UGCG 7357 2.6 11/18 (61%)
C14orf168 83544 6.7 6/18 (33%) CELSR2* 1952 2.5 8/18 (44%)
FBP1 2203 6.7 14/18 (78%) CRIM1 51232 2.5 11/18 (61%)
MYB 4602 6.7 14/18 (78%) FLJ90798* 219654 2.5 9/18 (50%)
RARA* 5914 6.7 12/18 (67%) KIF12 113220 2.5 7/18 (39%)
CaMKIINα 55450 6.3 18/18 (100%) LRIG1 26018 2.5 9/18 (50%)
AR* 367 6.2 10/18 (55%) LRP2* 4036 2.5 10/18 (55%)
ZNF552 79818 6.2 16/18 (89%) PHF15* 23338 2.5 12/18 (67%)
MIPEP* 4285 6.0 14/18 (78%) HSMNP1 55861 2.4 8/18 (44%)
BAI2 576 5.3 15/18 (83%) LOC123169 123169 2.4 12/18 (67%)
DP1L1 92840 5.3 15/18 (83%) PINK1* 65018 2.4 11/18 (61%)
VAV3 10451 5.3 12/18 (67%) PRKAR2B 5577 2.4 7/18 (39%)
KIAA0089 23171 5.2 17/18 (94%) TJP3* 27134 2.4 11/18 (61%)
GATA3 2625 5.1 15/18 (83%) CCND1 595 2.3 9/18 (50%)
QDPR 5860 5.1 11/18 (61%) CYBRD1 79901 2.3 10/18 (55%)
C1orf21 81563 4.9 11/18 (61%) KRT18 3875 2.3 10/18 (55%)
KIAA1143 57456 4.9 7/18 (39%) PURA 5813 2.3 9/18 (50%)
OIP106 22906 4.9 16/18 (89%) SREBF1* 6720 2.3 10/18 (55%)
AGR2 10551 4.6 10/18 (55%) CYB5R1 51706 2.2 6/18 (33%)
MGC4251 84336 4.6 13/18 (72%) DLG3* 1741 2.2 9/18 (50%)
FER1L3 26509 4.4 10/18 (55%) EEF1A2 1917 2.2 11/18 (61%)
C4A 720 4.1 11/18 (61%) GSTZ1 2954 2.2 9/18 (50%)
CRIP2 1397 4.0 15/18 (83%) LOC159090 159090 2.2 6/18 (33%)
NTN4 59277 4.0 10/18 (55%) MGC11242* 79170 2.2 10/18 (55%)
GJA1 2697 3.8 11/18 (61%) MGC18216* 145815 2.2 8/18 (44%)
CGI-111* 51015 3.7 14/18 (78%) NEIL1 79661 2.2 6/18 (33%)
CROT* 54677 3.6 15/18 (83%) XBP1* 7494 2.2 8/18 (44%)
DACH 1602 3.6 13/18 (72%) IRX5 10265 2.1 8/18 (44%)
DKFZP564D172 83989 3.6 10/18 (55%) RAB31 11031 2.1 9/18 (50%)
FGD3 89846 3.6 10/18 (55%) SSBP2 23635 2.1 7/18 (39%)
RNASE4* 6038 3.6 12/18 (67%) TGFB3 7043 2.1 8/18 (44%)
GLUL* 2752 3.3 11/18 (61%) BMPR1B 658 2.0 7/18 (39%)
FOXA1 3169 3.2 10/18 (55%) FLJ21174 79921 2.0 6/18 (33%)
MGC7036 196383 3.2 14/18 (78%) FLJ22386 79641 2.0 7/18 (39%)
MUC1* 4582 3.2 12/18 (67%) HSPB1* 3315 2.0 6/18 (33%)
NAV1 89796 3.1 13/18 (72%) IGFBP4* 3487 2.0 8/18 (44%)
RPLP1* 6176 3.1 12/18 (67%) MGC15737* 85012 2.0 8/18 (44%)
ALCAM 214 2.9 9/18 (50%) SPARCL1 8404 2.0 9/18 (50%)
HSD17B4* 3295 2.9 13/18 (72%) STARD10 * 10809 2.0 7/18 (39%)
  1. * Genes with known or putative high-affinity EREs mapping in the vicinity of the TSS.
  2. # Transcripts tags changing > 2-fold when compared with the average expression of ERα (-) tumors. Underlined genes correspond to the transcripts cross-validated among all three compared platforms.